The Adaptive experience: Observations and analysis of real-world clonoSEQ results

As the leading provider of clinical NGS MRD testing in the U.S., Adaptive Biotechnologies has an unparalleled ability to draw insight from our internal data. Leveraging this unique dataset, we can illustrate how, when and for which patient types MRD testing is currently being used by clinicians MRD testing is currently being used by clinicians. These data also enable publication of novel findings regarding the depth and duration of the response that clonoSEQ-tested patients are achieving.




This page is intended for use by healthcare professionals of the United States.

clonoSEQ® is available as a FDA-cleared in vitro diagnostic (IVD) test service provided by Adaptive Biotechnologies to detect minimal residual disease (MRD) in bone marrow samples from patients with multiple myeloma or B-cell acute lymphoblastic leukemia (B-ALL) , and blood or bone marrow from patients with chronic lymphocytic leukemia (CLL). clonoSEQ is also available for use in other lymphoid cancers as a CLIA-validated laboratory developed test (LDT) service. For important information about the FDA-cleared uses of clonoSEQ including test limitations, please visit clonoSEQ.com/technicalsummary.

*Blood-based MRD testing for patients with B-Cell acute lymphoblastic leukemia (B-ALL) and multiple myeloma is available as a CLIA-regulated laboratory developed test (LDT) service provided by Adaptive Biotechnologies. This use of clonoSEQ has not been approved or cleared by the FDA

Test Your clonoSEQ Knowledge

How much do you know about clonoSEQ MRD testing in clinical practice?

clonoSEQ MRD Quiz